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Th   e vaccine against H1N1 was initially issued in July 2009 
with no doubts regarding its beneﬁ  cial immunoprotective 
eﬀ   ect [1,2]. Recent reports have shown that adverse 
events are few and generally not life-threatening [3]. 
Th   ere  fore, a worldwide vaccination program was launched 
with very strong conﬁ  dence [4]. Herein, for the accumu-
lative record, I report a possible life-threatening reaction 
of the monovalent H1N1 vaccine in Th  ailand.
A 38-year-old pregnant woman (gestational age of 
25 weeks) was ﬁ  t and well and had regular antenatal care 
without any problems. She was given an H1N1 vacci  na-
tion and the following day developed diﬀ  use myalgia and 
minimal shortness of breath. Her condition continued to 
deteriorate, ultimately ending in respiratory failure on 
day 5 post-vaccination. On arrival at the intensive care 
unit, she was tachypneic, tachycardic, and hypotensive. 
Her chest ﬁ  lm demonstrated diﬀ  use bilateral lung inﬁ  l-
tration. She was eventually intubated and ventilated with 
high-concentra  tion oxygen and high positive end-expira-
tory pressure. She was found to have bloody secretions 
from tracheal aspiration. Acute lung injury with pulmo-
nary hemorrhage was, therefore, suspected.
A complete physical examination revealed a severe 
bilateral subconjunctival hemorrhage. No other abnor-
mali  ties were detected. Blood labs showed a leucopenia 
level of 2,600/mm3, mild anemia with hemoglobin of 
10 gm/dL, and a platelet count of 40,000/mm3. A coagu-
lation study was normal. She was also suﬀ  ering  from 
acute renal failure with a creatinine level of 3 mg/dL. 
Urinalysis demonstrated proteinuria with a quantitative 
count of around 1.2 gm/L with microscopic hematuria. A 
liver function test also showed mild transaminitis. 
Microbiological study and culture were negative. An 
echocardiogram showed severe pulmonary hypertension, 
possibly from severe acute lung injury.
Overall, she developed multiple organ failure, including 
acute respiratory distress syndrome (possibly from 
pulmonary hemorrhage), shock, acute renal failure with 
possible glomerulonephritis, and thrombocytopenia. 
Systemic autoimmune diseases, such as systemic lupus 
erythema  tosus or systemic vasculitis, were considered in 
the diﬀ   erential diagnosis, but all vasculitic screens, 
includ  ing anti-nuclear antibody, C3 and C4 levels, 50% 
hemolytic complement (CH50), anti-neutrophil cytoplasmic 
antibody, and anti-double-stranded DNA, were negative. 
Th   e patient’s clinical condition slowly improved over the 
following 7 days with aggressive organ support but no 
speciﬁ  c management.
In conclusion, the diagnosis of this patient remains 
unclear; however, vasculitis or an autoimmune disease is 
unlikely, and a severe adverse event following the H1N1 
vaccination could not be completely excluded. Physicians 
should remain alert to possible severe adverse reactions 
to this vaccine.
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